Clinical trials
Carcinoma, Transitional Cell clinical trials
Below are recruiting carcinoma, transitional cell clinical trials, each written for real people, not researchers. We’re tracking 41 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07227025RecruitingPhase 1/Phase 2
Study of amivantamab and olomorasib for KRAS G12C lung cancer
This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07589413Recruiting
Blood markers and fluid absorption during bladder cancer surgery
This study looks at how fluid absorbed during bladder cancer removal surgery affects cell-free DNA (tiny pieces of cancer DNA) in your blood. Researchers want to understand if these blood markers can help predict surgery outcomes and guide treatment decisions.
Lanzhou, GansuAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03288532RecruitingPhase 3
Adjuvant immunotherapy after kidney cancer surgery
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
AberdeenAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06820255RecruitingPhase 4
DNA repair and platinum chemo for advanced bladder cancer
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
RomeAges 18 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT07119996RecruitingPhase 1
Vitamin B3 to boost immunotherapy for bladder cancer
This trial tests whether taking vitamin B3 can help immunotherapy work better for people with bladder cancer. It’s for patients who have a certain type of bladder cancer and have had a recent infection that needed antibiotics.
Guangzhou, GuangdongAges 18 years+ - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Toronto, OntarioAges 18 years+ - NCT05456256RecruitingPhase 2
LP-300 plus chemo for lung cancer in never-smokers
This Phase 2 trial tests LP-300 with carboplatin and pemetrexed to treat advanced lung adenocarcinoma in people who have never smoked. It may help shrink tumors and slow the disease in a specific genetic group of lung cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with MRD
This trial tests a personalized cancer vaccine for people with certain cancers (bladder, stomach/esophagus, melanoma, or lung) who have no visible cancer after surgery but still have tiny bits of cancer DNA in their blood (called MRD). The vaccine is designed to train your immune system to attack any remaining cancer cells.
Orlando, FloridaAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75
Hear when a new Carcinoma, Transitional Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma, transitional cell?
- Yes. Clin2 currently lists 41 recruiting carcinoma, transitional cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma, transitional cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma, transitional cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.